GlassScriptPhysician profile
Steven P Harrell
NPI 1609918374
$12,254.96
in general payments reported to CMS, 2019-2025
43 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $560 · 2021: $1,790 · 2022: $2,156 · 2023: $2,520 · 2024: $1,940 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,944 · Education: $55.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,944.38 |
| Education | $55.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,049.42 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,787.30 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,644.66 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,605.27 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $466.97 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $449.44 | 2022-2025 | |
| Pfizer INC. | $399.68 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $242.89 | 2019-2023 | Dificid |
| Ardelyx, INC. | $235.95 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $234.02 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $232.59 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $205.09 | 2023-2025 | Dupixent |
| Celgene Corporation | $164.87 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $157.06 | 2021-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $153.04 | 2019-2024 | Linzess |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $131.68 | 2021-2023 | Injectafer |
| Nestle Healthcare Nutrition INC. | $93.60 | 2021-2023 | |
| Tersera Therapeutics LLC | $93.48 | 2021-2023 | Zoladex, Xermelo |
| Novo Nordisk INC | $92.49 | 2023-2024 | Wegovy |
| Celltrion USA INC. | $91.17 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Shire North American Group INC | $80.61 | 2019 | |
| Organon LLC | $69.51 | 2021-2025 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $59.13 | 2024-2025 | Zenpep |
| Ucb, INC. | $48.85 | 2019 | |
| Alnylam Pharmaceuticals INC. | $38.56 | 2022 | |
| Sandoz INC. | $37.17 | 2022-2024 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $33.54 | 2025 | Iqirvo |
| Lilly USA, LLC | $30.33 | 2024 | Omvoh |
| Csl Behring | $29.59 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $29.47 | 2024 | Stelara |
| Amgen INC. | $28.13 | 2022 | |
| Allergan, INC. | $27.18 | 2019 | |
| Shionogi INC | $26.05 | 2019 | |
| Evoke Pharma, INC. | $25.81 | 2020-2021 | |
| Romark Laboratories, Lc | $25.34 | 2019 | |
| Redhill Biopharma INC. | $19.08 | 2022 | |
| Ambu INC. | $19.06 | 2021 | |
| Ferring Pharmaceuticals INC. | $18.77 | 2024 | Rebyota |
| Vivus LLC | $17.38 | 2021 | |
| Endogastric Solutions, INC | $16.80 | 2023 | Esophyx |
| Shield Therapeutics INC | $16.56 | 2022 | |
| Amag Pharmaceuticals, INC. | $16.12 | 2021 | |
| Braintree Laboratories, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.